Nawara Hend M, Afify Said M, Hassan Ghmkin, Zahra Maram H, Seno Akimasa, Seno Masaharu
Department of Biotechnology and Drug Discovery, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.
Division of Biochemistry, Chemistry Department, Faculty of Science, Menoufia University, Menoufia 32511, Egypt.
Biomedicines. 2021 May 2;9(5):500. doi: 10.3390/biomedicines9050500.
Paclitaxel (PTX) is a chemotherapeutical agent commonly used to treat several kinds of cancer. PTX is known as a microtubule-targeting agent with a primary molecular mechanism that disrupts the dynamics of microtubules and induces mitotic arrest and cell death. Simultaneously, other mechanisms have been evaluated in many studies. Since the anticancer activity of PTX was discovered, it has been used to treat many cancer patients and has become one of the most extensively used anticancer drugs. Regrettably, the resistance of cancer to PTX is considered an extensive obstacle in clinical applications and is one of the major causes of death correlated with treatment failure. Therefore, the combination of PTX with other drugs could lead to efficient therapeutic strategies. Here, we summarize the mechanisms of PTX, and the current studies focusing on PTX and review promising combinations.
紫杉醇（PTX）是一种常用于治疗多种癌症的化疗药物。PTX是一种微管靶向剂，其主要分子机制是破坏微管动力学，诱导有丝分裂停滞和细胞死亡。同时，许多研究也评估了其他机制。自紫杉醇的抗癌活性被发现以来，它已被用于治疗许多癌症患者，并成为使用最广泛的抗癌药物之一。遗憾的是，癌症对PTX的耐药性被认为是临床应用中的一个广泛障碍，并且是与治疗失败相关的主要死亡原因之一。因此，将PTX与其他药物联合使用可能会产生有效的治疗策略。在此，我们总结了PTX的作用机制，以及目前针对PTX的研究，并综述了有前景的联合用药方案。
